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Abstract
Introduction: Raoultella species are Gram-negative non-motile, aerobic, oxidase-negative and catalase-positive rods that are members of the Enterobacterales order 
that are infrequently described as significant pathogens in human disease.
Objectives of the study: To report the incidence and the susceptibility levels of Raoultella species from clinical samples at a tertiary-care center in Hungary, during 
a 10-year study period (2008–2017).
Method: Data collection was performed electronically by searching the records of the laboratory information system (LIS), regarding the samples with significant 
colony counts for Raoultella spp.
Results: N=40 individual Raoultella isolates were identified (4.0±2.8/year, range: 0–9 isolates; highest in 2015, lowest in 2010 and 2011). Raoultella species were 
isolated from the following sample types: urine (catheterized and midstream): n=18, blood cultures: n=12, stool: n=6 and abscesses: n=4. 36 out of 40 isolates were R. 
ornithinolytica, while the remaining n=4 were R. planticola. All of the tested strains were susceptible to the group of β-lactam antibiotics.
Conclusion: Raoultella species should be considered as emerging pathogens in the context of human infections, especially in older individuals in people with severe 
immunosuppression. The results suggest that in our local settings, there was-on average-one isolation of Raoultella every three months from various clinical samples 
and β-lactams may be considered safe choices for empiric therapy.
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Introduction
Raoultella species are Gram-negative non-motile, aerobic, 
oxidase-negative and catalase-positive rods that are members of the 
Enterobacterales order (gut bacteria) [1,2]. The genus Raoultella was 
previously designated to the genus Klebsiella (as cluster II; e.g., K. 
ornithinolytica), but after extensive advancement in phylogenetic 
methods (16S rRNA and rDNA sequencing, bacterial RNA polymerase 
β subunit [rpoB] sequence-analysis), the genus Klebsiella was revised 
and the independent genus Raoultella was created in 2001 (named 
after Didier Raoult, a French bacteriologist) [3,4]. R. ornithinolytica is 
the most abundantly found both in clinical samples and in nature (in 
aquatic environments, soil and in different animals, such as fish, insects 
and ticks); however R. terrigena, R. planticola and R. trevisanii are also 
important members of the genus [2-4].
The existing literature on Raoultella infections in the context of 
human infections is scarce, as the incidence of these pathogens in 
clinically-relevant syndromes in low [5]. Most existing reports on 
these bacteria are associated with infections of the gastro-intestinal, 
hepatobiliary, urological and respiratory systems, while bloodstream-
infections, osteo-articular, soft tissue and ear-nose-throat (ENT) 
infections have also been published [6-11]. It should be noted, that 
the difficulty in the adequate identification (especially in low-resource 
settings) may be partly blamed for the infrequent characterization of 
these bacteria as significant pathogens [12]. Some reports even suggest 
that around 20% of Raoultella species are misidentified as Klebsiella 
(predominantly K. oxytoca) [13]. Nevertheless, with the advent of novel 
diagnostic modalities in routine use (such as whole-genome sequencing 
[WGS] and matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry [MALDI-TOF MS]) and reports on the emergence 
of multidrug-resistant strains of Raoultella, the clinical role of this 
genus should not be underestimated [14]. The aim of this study was to 
report the incidence and the susceptibility levels of Raoultella species 
from clinical samples at a tertiary-care center in Hungary, during a 10-
year study period (2008–2017).
Materials and methods
Study design and data collection
The present retrospective study was carried out using microbiological 
data collected corresponding to the time period between 2008.01.01.–
2017.12.31., at the Institute of Clinical Microbiology, University of 
Szeged. The Institute serves as the dedicated diagnostic institute 
of the Albert Szent-Györgyi Clinical Center, which is a 1,820-bed 
Gajdács M (2019) Epidemiology of Raoultella species in the context of human infections: A 10-year retrospective study in a tertiary-care hospital in Hungary
 Volume 20: 2-4Trends Med, 2019                doi: 10.15761/TiM.1000217
primary- and tertiary-care teaching hospital in the Southern Great 
Plain of Hungary (with an estimated population of over 400,000 
people, based on data from 2017) [15]. Data collection was performed 
electronically by searching the records of the laboratory information 
system (LIS), regarding the samples with significant colony counts 
for Raoultella spp. (>105 CFU/mL for urine samples, while >103 in 
case of other types of clinically-relevant samples; however, this was 
subject to interpretation by the senior clinical microbiologists, based 
on the information provided on the clinical request forms for the 
microbiological analysis and international guidelines) [16]. Only the 
first isolate per patient was included in the study; however, isolates with 
different antibiotic-susceptibility patterns from the same patient were 
considered as different individual isolates. To evaluate the demographic 
characteristics of these infections, patient data was also collected, which 
was limited to sex, age at sample submission, and inpatient/outpatient 
status [16]. The study was deemed exempt from ethics review by the 
Institutional Review Board and informed consent was not required as 
data anonymity was maintained.
Sample processing and identification 
The processing of relevant samples arriving to the Institute of 
Clinical Microbiology was carried out according to guidelines in 
routine clinical bacteriology. Between 2008–2012, the BD Bactec 
(Beckton Dickinson, Franklin Lakes, NJ, USA) detection system was 
employed for the incubation of blood culture bottles, whilst from 2013 
onwards, the BacT/ALERT 3D (bioMérieux, Marcy-l’Étoile, France) 
detection system was used. Blood culture bottles were incubated for 5 
days (21 days, if endocarditis was suspected) in the abovementioned 
detection systems [17]. The processing of urine samples was as follows: 
10 µL of each un-centrifuged urine sample was cultured on UriSelect 
chromogenic agar plates (Bio-Rad, Berkeley, CA, USA) with a calibrated 
loop, according to the manufacturer’s instructions and incubated at 
37°C for 24–48 h, aerobically [15]. The workup of faecal samples was 
performed on the appropriate non-selective and selective media. If the 
relevant pathogens presented in significant colony count, the plates 
were passed on for further processing. 
Between 2008–2012, presumptive phenotypic (biochemical 
reaction-based) methods and VITEK 2 ID (bioMérieux, Marcy-l’Étoile, 
France) were used for bacterial identification, while after 2013, this 
was complemented by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonik 
Gmbh. Gr., Bremen, Germany). Bacterial cells were transferred to a 
stainless-steel target. An on-target extraction was performed by adding 
1 ml of 70% formic acid prior to the matrix. After drying at ambient 
temperature, the cells were covered with 1 ml matrix (α-cyano-4-
hydroxy cinnamic acid in 50% acetonitrile/2.5% trifluoro-acetic acid). 
Mass spectrometry was performed by the Microflex MALDI Biotyper 
(Bruker Daltonics, Bremen, Germany) in positive linear mode across 
the m/z range of 2 to 20 kDa; for each spectrum, 240 laser shots at 60 Hz 
in groups of 40 shots per sampling area were collected [18]. The MALDI 
Biotyper RTC 3.1 software (Bruker Daltonics) and the MALDI Biotyper 
Library 3.1 were used for spectrum analysis.
Antimicrobial susceptibility testing (AST)
Antimicrobial susceptibility testing (AST) was performed using 
the Kirby–Bauer disk diffusion method and when appropriate, E-test 
(Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) plates. 
The interpretation of the results was based on EUCAST breakpoints 
for Enterobacteriaceae (Enterobacterales). The following antibiotics 
were tested: amoxicillin/clavulanic acid, piperacillin/tazobactam, 
ceftazidime, ceftriaxone, cefepime, imipenem, meropenem, gentamicin, 
tobramycin, amikacin, norfloxacin, ciprofloxacin, levofloxacin and 
sulfamethoxazole/trimethoprim. During data analysis, intermediately-
susceptible results were grouped with and reported as resistant. If 
extended-spectrum beta-lactamase (ESBL)-production was suspected, 
detection was carried out based on EUCAST recommendations, 
using AmpC-ESBL Detection Set (MAST Diagnostica GmbH, 
Reinfeld, Germany), according to the manufacturer’s instructions. 
Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, 
Proteus mirabilis ATCC 35659, Escherichia coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603 and Pseudomonas aeruginosa ATCC 27853 
were used as quality control strains [16]. 
Statistical analysis
Descriptive statistical analysis (including means or medians with 
ranges and percentages to characterize data) was performed using 
Microsoft Excel 2013 (Redmond, WA, Microsoft Corp.). 
Results
During the 10-year study period, a total of 40 individual Raoultella 
isolates were identified (4.0±2.8/year, range: 0–9 isolates; highest 
in 2015, lowest in 2010 and 2011). The number of isolates in the 
first half of the surveillance period (2008–2012) was n=12, while for 
2013–2017, this number was n=28. 32 out of 40 isolates were from 
samples originating from inpatient departments. Raoultella species 
were isolated from the following sample types: urine (catheterized and 
midstream): n=18, blood cultures: n=12, stool: n=6 and abscesses: n=4. 
36 out of 40 isolates were R. ornithinolytica, while the remaining n=4 
were R. planticola. The affected patients presented with a pronounced 
male dominance (29 out of 40); the age distribution of patients was the 
following: 0–5 years: n=8, 6–35 years: n=2 36-59 years: n=12 and 60 
years of age or older: n=18. The indications specified on the sample 
submission forms were the following: diseases of the urinary system 
(infection, anatomical abnormality): n=18, cardiovascular illness: n=5, 
abdominal pain: n=5, infection (not specified): n=3, diseases of the 
central nervous system (CNS): n=2, sepsis: n=2, pneumonia: n=2 and 
other: n=3.
All of the tested strains were susceptible to the group of β-lactam 
antibiotics (40 out of 40; from ampicillin to meropenem, respectively), 
while 8/40 of isolates were resistant to norfloxacin, 6/40 to ciprofloxacin 
and levofloxacin, 5/40 to sulfamethoxazole/trimethoprim and 2/60 to 
the tested aminoglycosides, respectively. No ESBL- or AmpC-producing 
strain was detected during the study period.
Discussion
The present study reports on the epidemiological features of 
Raoultella infections at a tertiary-care hospital in Hungary over a 
period of a decade (2008-2017). Due to the developments in diagnostic 
technologies in routine clinical microbiology (e.g., MALDI-TOF MS), 
the prevalence of bacterial species that were previously considered 
as rare will most probably increase, which is reflected in the increase 
in the interest towards these bacteria in the literature [1-11,19]. The 
clinical role and prognosis of Raoultella infections highly depend on 
the health status of the patient: the risk of sequelae is higher in older, 
co-morbid patient with invasive infections, therefore the awareness of 
the clinicians regarding the epidemiology and susceptibility-levels of 
these bacteria is of utmost importance [20-22]. In case of those patients, 
the initiation of prompt antibiotic therapy is crucial for recovery, while 
in immunocompetent patients, symptoms may resolve with supportive 
Gajdács M (2019) Epidemiology of Raoultella species in the context of human infections: A 10-year retrospective study in a tertiary-care hospital in Hungary
 Volume 20: 3-4Trends Med, 2019                doi: 10.15761/TiM.1000217
3. Drancourt M, Bollet C, Carta A, Rousselier P (2001) Phylogenetic analyses of 
Klebsiella species delineate Klebsiella and Raoultella gen. nov., with description of 
Raoultella ornithinolytica comb. nov., Raoultella terrigena comb. nov. and Raoultella 
planticola comb. nov. Int J Syst Evol Microbiol 51: 925-932.
4. Kanki M, Yoda T, Tsukamoto T, Shibata T (2002) Klebsiella pneumoniae produces 
no histamine: Raoultella planticola and Raoultella ornithinolytica strains are histamine 
producers. Appl Environ Microbiol 68: 3462-3466.
5. Seng P, Boushab BM, Romain F, Gouriet F, Bruder N, et al. (2016) Emerging role 
of Raoultella ornithinolytica in human infections: a series of cases and review of the 
literature. Int J Infect Dis 45: 65-71. [Crossref] 
6. Sekowska A (2017) Raoultella spp.-clinical significance, infections and susceptibility 
to antibiotics. Folia Microbiol (Praha) 62: 221-227.
7. Buyukcam A, Liste U, Bicakcigil A, Kara A, Sancak B (2019) A case of Raoultella 
ornithinolytica urinary tract infection in a pediatric patient. J Infect Chemother 25: 
467-469.
8. Sener D, Cokhras H, Camcioglu Y, Akcakaya N, Cakir E (2011) Raoultella infection 
causing fever of unknown origin. Ped Infect Dis J 30: 1122-1123.
9. Haruki Y, Hagiya H, Sakuma A, Murase T, Sugiyama T, et al. (2014) Clinical 
characteristics of Raoultella ornithinolytica bacteremia: a case series and literature 
review. J Infect Chemother 20: 589-591. [Crossref] 
10. Van Cleve JR, Boucher BA, Smith DV, Croce MA (2018) Ventilator associated 
pneumonia caused by Raoultella ornithinolytica in two immunocompetent trauma 
patients. Respir Med Case Rep 24: 135-137.
11. Podschun R, Acktun H, Okpara J, Linderkamp O, Ullmann U, et al. (1998) Isolation 
of Klebsiella planticola from newborns in a neonatal ward. J Clin Microbiol 36: 2331-
2332. [Crossref] 
12. Park JS, Hong KH, Lee HJ, Choi SH, Song SH, et al. (2011) Evaluation of three 
phenotypic identification systems for clinical isolates of Raoultella ornithinolytica. J 
Med Microbiol 60: 492-499.
13. Mori M, Ohta M, Agata N, Kido N, Arakawa Y, et al. (1989) Identification of species 
and capsular types of Klebsiella clinical isolates, with special reference to Klebsiella 
planticola. Microbiol Immunol 33: 887-895.
14. Gajdács M, Urbán E (2019) Resistance trends and epidemiology of Citrobacter-
enterobacter-serratia in urinary tract infections of inpatients and outpatients 
(RECESUTI): A 10-Year Survey. Medicina 55: 285.
15. Gajdács M, Burián K, Terhes G (2019) Resistance levels and epidemiology of non-
fermenting gram-negative bacteria in urinary tract infections of inpatients and 
outpatients (RENFUTI): A 10-year epidemiological snapshot. Antibiotics 8: 143.
16. Gajdács M, Urbán E (2019) The relevance of anaerobic bacteria in brain abscesses: A 
ten-year retrospective analysis (2008-2017). Infect Dis 51: 779-781.
17. Schubert S, Kostrzewa M (2017) MALDI-TOF MS in the microbiology laboratory: 
Current trends. Curr Issues Mol Biol 23: 17-20.
18. de Jong E, de Jong AS, Smidts-van den Berg N, Rentenaar RJ (2013) Differentiation of 
Raoultella ornithinolytica/planticola and Klebsiella oxytoca clinical isolates by matrix-
assisted laser desorption/ionization-time of flight mass spectrometry. Diagn Microbiol 
Infect Dis 75: 431-433.
19. Lam PW, Tadros M, Fong IW (2018) Mandibular osteomyelitis due to Raoultella 
species. JMM Case Rep 5: e005140.
20. Gajdács M, Szabó A (2019) Physicians’ opinions towards antibiotic use and resistance 
in the southeastern region of Hungary. 
21. Gajdács M (2019) Intravenous or oral antibiotic therapy: Sophie’s choice? Gen Int Med 
Clin Innov 4: 1-2.
22. Tominaga T (2018) Rapid detection of Klebsiella pneumoniae, Klebsiella oxytoca, 
Raoultella ornithinolytica and other related bacteria in food by lateral-flow test strip 
immunoassays. J Microbiol Methods 147: 43-49.
23. Demiray T, Koroglu M, Ozbek A, Altindis M (2016) A rare cause of infection, 
Raoultella planticola: emerging threat and new reservoir for carbapenem resistance. 
Infection 44: 713-7.
24. Wang X, Wang Y, Zhou Y, Wang Z, Wang Y, et al. (2019) Emergence of colistin 
resistance gene mcr-8 and its variant in Raoultella ornithinolytica. Front Microbiol 10: 
228.
25. Zurfluh K, Hachler H, Nuesch-Inderbinen M, Stephan R (2013) Characteristics of 
extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae 
Isolates from rivers and lakes in Switzerland. Appl Environ Microbiol 79: 3021-3026.
therapy as well [1-8]. The virulence factors of Raoultella are thought 
to be similar to the ones of Klebsiella species due to their phylogenic 
similarities, however, no such correlation was found in vivo [12,23].
Based on the findings in the literature, Raoultella species are usually 
broadly sensitive to most antibiotics against Gram-negative bacteria: 
this was demonstrated in our study as well, where all β-lactams may 
be considered as safe choices for empiric therapy [1-11]. Other reports 
in the literature have also highlighted β-lactams as safe alternatives 
for therapy, due to very low resistance levels. However, it should 
be remembered that these bacteria (similarly to Klebsiella spp.) are 
intrinsically resistant to ampicillin, due to a chromosomally-encoded 
β-lactamase enzyme [12,23]. Nonetheless, MDR strains of Raoultella 
have been described, producing a variety of β-lactamases (Ambler 
class A, B and D), including SHV-, TEM- and CTX-M-type extended-
spectrum β-lactamases (ESBLs) and these bacteria have been reported 
as potential reservoirs for carbapenemase and colistin-resistance genes 
[24-28]. 
The limitations of this study should be reported: the study was 
retrospective, thus the symptoms of individual patients affected by 
these infections could not be recorded in real-time. Additionally, 
the molecular characterization of resistance determinants in the 
mentioned isolates was not performed; therefore non-susceptibility was 
characterized by phenotypic methods only [15].
Conclusions
Although infrequently isolated (or identified), Raoultella species 
should be considered as emerging pathogens in the context of human 
infections, especially in older individuals in people with severe 
immunosuppression. The results suggest that in our local settings, there 
was-on average-one isolation of Raoultella every three months from 
various clinical samples and β-lactams may be considered safe choices 
for empiric therapy of these infections, taking into account that the 
emergence of resistant mutants is possible. The surveillance of rarely 
isolated species over long periods of time may help ascertain their true 
clinical role in human infections. 
Author contributions
M.G. conceived and designed the study, performed data collection 
and analysis, wrote and revised the full paper.
Funding
This research received no external funding.
Acknowledgments
M.G. was supported by the National Youth Excellence Scholarship 
[Grant Number NTP-NTFÖ-18-C-0225] and the ESCMID Mentorship 
and Observership Programme.
Conflicts of interest
The author declares no conflicts of interest, monetary or otherwise.
References
1. Adeolu M, Alnajar S, Naushad SS, Gupta R (2016) Genome-based phylogeny and 
taxonomy of the “Enterobacteriales”: proposal for Enterobacterales ord. nov. divided 
into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. 
nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and 
Budviciaceae fam. nov. Int J Syst Evol Microbiol 66: 5575-5599.
2. Chun S, Yun JW, Huh HJ, Lee NY (2015) Clinical characteristics of Raoultella 
ornithinolytica bacteremia. Infection 43: 59-64.
Gajdács M (2019) Epidemiology of Raoultella species in the context of human infections: A 10-year retrospective study in a tertiary-care hospital in Hungary
 Volume 20: 4-4Trends Med, 2019                doi: 10.15761/TiM.1000217
26. Abid IN (2016) Emergence of Raoultella ornithinolytica producing AmpC-beta-
lactamases in the different clinical specimens. J Nat Res Sci 6: 124-129.
27. Castanheira M, Deshpande LM, DiPersio JR, Kang J, Weinstein MP, et al. (2009) 
First descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): 
Report from the SENTRY antimicrobial surveillance program. J Clin Microbiol 47: 
4129-4130.
Copyright: ©2019 Gajdács M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and source are credited.
